AbbVie Already Dividend King? Why Apogee Deal Could Cement a Dynasty
AbbVie has quietly built a credible dividend track record since its 2013 spin-off from Abbott. The $10.9B Apogee deal...
Understand the reasons why investing is often considered a superior choice to saving for future financial goals. Take charge of your finances.
27,503 articlesAbbVie has quietly built a credible dividend track record since its 2013 spin-off from Abbott. The $10.9B Apogee deal...
Oklo stock just popped on news that the Department of Energy opened talks with multiple firms. This article breaks do...
When a MongoDB director sells a sizable block of shares, investors pause to weigh the meaning. This article breaks do...
A director’s stock sale can spark worry, but not every insider move is a warning. This guide shows how to assess trad...
The EU is gearing up for a major MiCA update in 2027 to cover non‑EU stablecoin issuers and tokenized payments. This ...
A Brazilian fund made a sizable bet on MercadoLibre even as the stock slid over the past year. This article unpacks t...
Big companies are tying AI tool use to career moves. This deep-dive explains how accenture tracking whether employees...
July 2026 brings a fresh wave of opportunities in semiconductors. This guide reveals five names with durable demand, ...
When a fund exits its Brookdale Senior Living stake, it raises questions about momentum and risk. This guide breaks d...
Executives gathered at the Fortune CEO Initiative dinner to debate debt risks, global diplomacy, and the role of busi...
Palantir has sparked debate among investors with rapid growth and high expectations. This guide breaks down whether p...
Prospect Capital offers a striking 20%+ yield, but its long-run performance raises questions. This article lays out a...